Does hepatitis B vaccination reduce the risk of HBV reactivation associated with immunosuppressive therapy?  

Hepatitis B reactivation is a critical concern when patients are undergoing immunosuppressive therapy, often described as 'deadly but preventable.' Screening for HBV is strongly advised before initiating biologic therapies, targeted synthetic therapies, or high-dose immunosuppression, including HBsA...

Thanks for the question and we apologize that our answer reads somewhat ambiguously as the answer to that is NO we do not vaccinate isolated anti-HBcore patients- we reworded our 'answer' to this question which we believe is clearer.